Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page
Price
Target price
€2.65

€2.65

-2.550%
-0.1
-2.550%
€4.00

€4.00

 
Latest predictions
€4.00
20.11.20
buy
€5.00
01.11.20
buy
-
28.10.20
€5.00
17.10.20
buy
-
25.08.20
buy
€9.00
10.08.20
buy
Your prediction

Paion AG Stock

A loss of -2.550% shows a downward development for Paion AG.
We see a rather positive sentiment for Paion AG with 10 Buy predictions and 2 Sell predictions.
With a target price of €4.00 there is a hugely positive potential of 50.943% for Paion AG compared to the current price of €2.65.

Pros and Cons of Paion AG in the next few years

Pros
1
Future proof or reliable business model
1
Some uniques
1
Innovative
1
Fair valuation
1
Revenue growth >5% per year expected
Cons
1
Higher risks for its business
1
Dependend from few customers or products

Comments

Published 02.01.20
Prediction Buy
Perf. (%) -0.49%
Target price
Change

Buy beendet

Buy Paion AG

Show more
Not a member yet? Sign up for free!

Other discussions about Paion AG Stock

New thread Forum

News

DGAP-Adhoc: PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
DGAP-Adhoc: PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2020
DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2020
DGAP-News: PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.
DGAP-News: PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.
DGAP-News: PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2020
DGAP-News: PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2020
DGAP-News: PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA
DGAP-News: PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA
DGAP-News: PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA
DGAP-News: PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA
DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE PROGRAM FOR REMIMAZOLAM IN BELGIUM
DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE PROGRAM FOR REMIMAZOLAM IN BELGIUM
DGAP-Adhoc: PAION AG: YICHANG HUMANWELL RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN CHINA
DGAP-Adhoc: PAION AG: YICHANG HUMANWELL RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN CHINA
DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA
DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA
DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES
DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES
DGAP-News: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
DGAP-News: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
DGAP-Adhoc: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
DGAP-Adhoc: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE FOR REMIMAZOLAM IN ITALIAN HOSPITAL
DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE FOR REMIMAZOLAM IN ITALIAN HOSPITAL